NextCell Pharma AB (STO:NXTCL)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.118
-0.042 (-3.62%)
Apr 29, 2026, 1:31 PM CET
-0.18%
Market Cap 129.22M
Revenue (ttm) 9.83M
Net Income (ttm) -38.79M
Shares Out 111.39M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 168,523
Average Volume 714,017
Open 1.076
Previous Close 1.160
Day's Range 1.076 - 1.180
52-Week Range 0.630 - 1.784
Beta 0.74
RSI 39.36
Earnings Date May 28, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 24
Stock Exchange Nasdaq Stockholm
Ticker Symbol NXTCL
Full Company Profile

Financial Performance

In 2025, NextCell Pharma AB's revenue was 9.83 million, a decrease of -11.13% compared to the previous year's 11.06 million. Losses were -38.79 million, 10.4% more than in 2025.

Financial Statements

News

There is no news available yet.